Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 17

1.
2.

Importance of cost-effectiveness and value in cancer care and healthcare policy.

Kang R, Goodney PP, Wong SL.

J Surg Oncol. 2016 Sep;114(3):275-80. doi: 10.1002/jso.24331. Review.

3.

Exploratory Cost-Effectiveness Analysis of Response-Guided Neoadjuvant Chemotherapy for Hormone Positive Breast Cancer Patients.

Miquel-Cases A, Retèl VP, Lederer B, von Minckwitz G, Steuten LM, van Harten WH.

PLoS One. 2016 Apr 28;11(4):e0154386. doi: 10.1371/journal.pone.0154386.

4.

Trends in Local Therapy Utilization and Cost for Early-Stage Breast Cancer in Older Women: Implications for Payment and Policy Reform.

Shirvani SM, Jiang J, Likhacheva A, Hoffman KE, Shaitelman SF, Caudle A, Buchholz TA, Giordano SH, Smith BD.

Int J Radiat Oncol Biol Phys. 2016 Jun 1;95(2):605-16. doi: 10.1016/j.ijrobp.2016.01.059.

PMID:
27034179
5.

Cost-effectiveness of alternative strategies for integrating MRI into breast cancer screening for women at high risk.

Ahern CH, Shih YC, Dong W, Parmigiani G, Shen Y.

Br J Cancer. 2014 Oct 14;111(8):1542-51. doi: 10.1038/bjc.2014.458.

6.

Trends and clinical implications of preoperative breast MRI in Medicare beneficiaries with breast cancer.

Killelea BK, Long JB, Chagpar AB, Ma X, Soulos PR, Ross JS, Gross CP.

Breast Cancer Res Treat. 2013 Aug;141(1):155-63. doi: 10.1007/s10549-013-2656-1.

7.

Surgical treatment differences among Latina and African American breast cancer survivors.

Campesino M, Koithan M, Ruiz E, Glover JU, Juarez G, Choi M, Krouse RS.

Oncol Nurs Forum. 2012 Jul;39(4):E324-31. doi: 10.1188/12.ONF.E324-E331.

8.

ESTIMATING TREATMENT EFFECTS ON HEALTHCARE COSTS UNDER EXOGENEITY: IS THERE A 'MAGIC BULLET'?

Basu A, Polsky D, Manning WG.

Health Serv Outcomes Res Methodol. 2011 Jul 1;11(1-2):1-26.

9.

Comparative effectiveness of screening and prevention strategies among BRCA1/2-affected mutation carriers.

Grann VR, Patel PR, Jacobson JS, Warner E, Heitjan DF, Ashby-Thompson M, Hershman DL, Neugut AI.

Breast Cancer Res Treat. 2011 Feb;125(3):837-47. doi: 10.1007/s10549-010-1043-4.

10.

Overview of methods to estimate the medical costs of cancer.

Barlow WE.

Med Care. 2009 Jul;47(7 Suppl 1):S33-6. doi: 10.1097/MLR.0b013e3181a2d847.

11.

Cost-effectiveness analysis of mammography and clinical breast examination strategies: a comparison with current guidelines.

Ahern CH, Shen Y.

Cancer Epidemiol Biomarkers Prev. 2009 Mar;18(3):718-25. doi: 10.1158/1055-9965.EPI-08-0918.

12.

Differences among the elderly in the treatment costs of colorectal cancer: how important is race?

Wright GE, Barlow WE, Green P, Baldwin LM, Taplin SH.

Med Care. 2007 May;45(5):420-30.

13.

Trends in breast conserving surgery among Asian Americans and Pacific Islanders, 1992-2000.

Goel MS, Burns RB, Phillips RS, Davis RB, Ngo-Metzger Q, McCarthy EP.

J Gen Intern Med. 2005 Jul;20(7):604-11.

15.

Quality of life of 5-10 year breast cancer survivors diagnosed between age 40 and 49.

Casso D, Buist DS, Taplin S.

Health Qual Life Outcomes. 2004 May 18;2:25.

16.

Outcomes and quality of life following breast cancer treatment in older women: when, why, how much, and what do women want?

Mandelblatt J, Figueiredo M, Cullen J.

Health Qual Life Outcomes. 2003 Sep 17;1:45. Review.

17.
Items per page

Supplemental Content

Support Center